Past Events
Past Events
Verona Pharma Full Year 2019 Financial Results and Conference Call
Conference call time: 9.00 am EST / 2.00 pm GMT.
To participate, please dial one of the following numbers and reference conference ID 5394158:
- 866-940-4574 for callers in the United States
- 0800 028 8438 for callers in the United Kingdom
- 0800 181 5287 for callers in Germany
Webcast
Supporting materials
LSX World Congress 2020
Verona Pharma to Report 4 Week Phase 2b COPD Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
Webcast
Jefferies 2019 London Healthcare Conference
Webcast
Supporting materials
Stifel 2019 Healthcare Conference
Supporting materials
Guggenheim Healthcare Talks Idea Forum | Neuro/Immunology Day
Supporting materials
Verona Pharma Third Quarter 2019 Financial Results and Conference Call
To participate, please dial one of the following numbers and reference conference ID 6498479:
866-940-4574 for callers in the United States
0800 028 8438 for callers in the United Kingdom
0800 181 5287 for callers in Germany
Webcast
2019 H.C. Wainwright 21st Annual Global Investment Conference
Supporting materials
Ensifentrine (RPL554) Positive Data from 7-Day Phase 2 Clinical Trial in COPD Patients with Dry Powder Inhaler Formulation
Verona Pharma Second Quarter 2019 Financial Results and Conference Call
Webcast
2019 Wedbush PacGrow Healthcare Conference
Supporting materials
BTIG Biotechnology Conference 2019
Jefferies 2019 Global Healthcare Conference
Jan-Anders Karlsson, Chief Executive Officer and Executive Director
Supporting materials
Expanded Analysis of Clinical Data at ATS 2019
Supporting materials
Investor & Analyst R&D Forum London 2019
Webcast
Supporting materials
Verona Pharma First Quarter 2019 Financial Results and Conference Call
Webcast
H.C Wainwright Global Life Sciences Conference
Supporting materials
Verona Pharma presents at Ligand Pharmaceuticals Analyst Day
Supporting materials
Cowen and Company 39th Annual Health Care Conference
Webcast
Supporting materials
Verona Pharma Full Year 2018 Financial Results and Conference Call
Webcast
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Webcast
Supporting materials
Citi Healthcare Conference
Verona Pharma to Present at Stifel 2018 Healthcare Conference
Verona Pharma Third Quarter 2018 Financial Results and Conference Call
Webcast
Investor & Analyst R&D Forum
Webcast
Supporting materials
Verona Pharma Presents Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress
Webcast
Supporting materials
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved